Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously ...

Being out of care doesn’t have to be permanent, and many people can restart HIV treatment. The sooner PWH restart treatment, ...

More than 40 years of AIDS research has led to significant advancements in treatment and prevention. Drugs to treat the infection continued to improve, as did patient outcomes. But now there's another ...

Pseudoscience has recently re-emerged in the U.S. While much of it concerns vaccines, an "oldie" is again making the rounds: HIV is neither the cause nor the sole cause of AIDS. This nonsense has been ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012 as a treatment for people with HIV that no longer responded to ...

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV.

LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus’ transmission. In a statement ...

According to UNAIDS, in 2024, about 40.8 million people around the world were living with the human immunodeficiency virus (HIV) — a virus that can lead to acquired immunodeficiency syndrome (AIDS) if ...

The U.S. Food and Drug Administration (FDA) approved Yeztugo, a powerful, long-acting injection developed by Gilead Sciences, as a twice-yearly preventive treatment against HIV. The move has ignited ...

June 18 (UPI) --The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and possibly eradicate the disease. The drug's scientific name ...

Oct 2 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV ...